Spark Therapeutics Inc  

(Public, NASDAQ:ONCE)   Watch this stock  
Find more results for once
55.77
+1.80 (3.34%)
After Hours: 55.77 0.00 (0.00%)
Dec 8, 4:39PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 52.74 - 55.89
52 week 21.20 - 65.99
Open 53.74
Vol / Avg. 573,816.00/562,092.00
Mkt cap 1.83B
P/E     -
Div/yield     -
EPS -3.32
Shares 30.77M
Beta     -
Inst. own 91%
Mar 7, 2017
Q4 2016 Spark Therapeutics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 5, 2016
Selecta Biosciences Inc Conference Call to Discuss License Agreement with Spark Therapeutics Inc
Dec 5, 2016
Spark Therapeutics Inc Corporate Call
Nov 17, 2016
Spark Therapeutics Inc at Jefferies Healthcare Conference
Nov 16, 2016
Spark Therapeutics Inc at Stifel Healthcare Conference
Nov 8, 2016
Spark Therapeutics Inc at Credit Suisse Healthcare Conference
Nov 3, 2016
Q3 2016 Spark Therapeutics Inc Earnings Release
Nov 3, 2016
Q3 2016 Spark Therapeutics Inc Earnings Call - Webcast
Oct 11, 2016
Spark Therapeutics Inc at Jeffries Gene Editing/Therapy Summit
Sep 28, 2016
Spark Therapeutics Inc at Leerink Partners Rare Disease & IO Roundtable Series
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -2499.44% -213.59%
Operating margin -2543.10% -214.46%
EBITD margin - -206.61%
Return on average assets -31.86% -22.43%
Return on average equity -35.06% -36.28%
Employees 113 -
CDP Score - -

Address

3737 Market St Ste 1300
PHILADELPHIA, PA 19104-5543
United States - Map
+1-212-7906248 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Spark Therapeutics, Inc. (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs). Its product candidates include SPK-CHM and SPK-FIX. Its product development portfolio includes product candidates targeting expression of genes in the liver, with an initial focus on hematologic disorders. It is engaged in the development and commercialization of SPK-FIX product candidates for the treatment of hemophilia B. The Company is developing a lead product candidate for the treatment of a form of Batten disease in SPK-TPP1 program. The Company is also conducting preclinical studies on a product candidate for the treatment of Huntington's disease, a hereditary genetic disorder.

Officers and directors

Steven M. Altschuler M.D. Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Katherine A. High M.D. President, Co-Founder, Chief Scientific Officer, Director
Age: 64
Bio & Compensation  - Reuters
Jeffrey D. Marrazzo Chief Executive Officer, Co-Founder, Director
Age: 37
Bio & Compensation  - Reuters
Stephen W. Webster Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
John Furey Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
Rogerio Vivaldi M.D. Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
Joseph W. La Barge Esq. Secretary
Age: 43
Bio & Compensation  - Reuters
A. Lorris Betz M.D. Ph.D. Director
Age: 69
Bio & Compensation  - Reuters
Lars G. Ekman M.D. Ph.D. Independent Director
Age: 66
Bio & Compensation  - Reuters
Anand Mehra M.D. Independent Director
Age: 40
Bio & Compensation  - Reuters